Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• SHP2 is crucial in signaling pathways implicated in cancer and neurodevelopmental disorders.
• Allosteric inhibitors aim to control SHP2 activity by targeting its regulatory sites.
• Oncogenic mutations, like E76K, lock SHP2 in an active conformation, exposing its catalytic cleft.

Purpose of the Study:

• To investigate the dynamic structural changes of SHP2 in different states, particularly in response to oncogenic mutations.
• To analyze the impact of mutations on known allosteric inhibitor binding sites.
• To discover novel allosteric binding pockets on SHP2.

Main Methods:

• Extensive molecular modeling and simulations were employed to study SHP2 dynamics.
• Analysis focused on the effects of oncogenic mutations on known allosteric inhibitor binding sites.
• Multi-tier screening was utilized to identify potential drug candidates for newly identified binding sites.

Main Results:

• The study elucidated the dynamic properties of SHP2 across various conformational states.
• Oncogenic mutations were shown to affect the accessibility and dynamics of known allosteric binding sites.
• A novel allosteric binding pocket in SHP2 solution structures was identified and characterized.
• Potential binders for this new site were identified through multi-tier screening.

Conclusions:

• Understanding SHP2's dynamic behavior and mutation effects is key for therapeutic development.
• The discovery of a new allosteric site offers opportunities for developing novel inhibitors.
• Targeting distinct SHP2 allosteric sites with multiple inhibitors could provide a strategy to combat SHP2-driven cancers.